News
Johnson & Johnson said its drug-device combo for bladder cancer achieved a high rate of complete responses lasting at least a ...
Merck KGaA in talks to acquire SpringWorks Therapeutics for $47/share ($3.5B), gaining cancer drugs Ogsiveo and Gomekli. Deal ...
Amgen is the latest in a series of biopharma companies to tout a massive new US-based investment in manufacturing.
Gilead’s HIV drug business grew while its Covid drug sales tanked in the first quarter of 2025, as the company recorded the ...
Akeso Biopharma won first-line approval in China for its lung cancer drug ivonescimab, a new immunotherapy that it believes ...
In an interview with PBS' 'NewsHour' co-anchor and co-managing editor Amna Nawaz on Thursday, Marty Makary expanded on his ...
When the board of Belgian biotech Galapagos asked Paul Stoffels to become CEO, he told them he was only interested in doing ...
ALX Oncology’s efforts to progress a CD47 combo hit a major speed bump. The company said Friday that two trials ...
AbbVie CEO Rob Michael said the company will invest $10 billion in the US over the next decade, as the threat of ...
The FDA has asked Novavax to commit to producing post-marketing data of its Covid vaccine, the clearest example yet that the ...
Sanofi reports Q1 growth with Altuviiio sales doubling to €251M and Dupixent reaching €3.5B; company terminates two cancer ...
Nicholas Johnston launches Alis Biosciences, targeting struggling biotechs with $30B in trapped capital and aiming to return cash to shareholders.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results